Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
- New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved' by early-start
- 07/31/2025
|
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
- Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/10/2025
|
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
- PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex”) on behalf of the company's long-term shareholders.
- 06/16/2025
|
Does Anavex's Alzheimer's Drug Actually Confer Benefit?
- Anavex Life Sciences' OLE study demonstrates that its Alzheimer's drug works for years beyond the clinical study. The OLE expands efficacy to include patients' behavioral abilities. The Anavex drug may offer years of extra mental lucidity and greater self-sufficiency among Alzheimer's patients. The EU's approval of Blarcamesine could increase Anavex's market value from $800 million to $8 billion.
- 05/15/2025
|
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
- Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early. These result could lead to European Medicines Agency approval. The benefits of blarcamesine may increase over time due to reduced oxidative stress, though side effects like diziness and confusion may occur. Given the lack of effective Alzheimer's treatments, I cautiously recommend buying Anavex stock based on these promising results.
- 05/15/2025
|
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference
- 05/14/2025
|
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
- 05/13/2025
|
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
- Company to host a webcast today at 8:30 a.m. Eastern Time
- 05/13/2025
|
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
- Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET
- 05/06/2025
|
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
- Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025 NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the successful completion of enrollment in its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia (ANAVEX3-71-SZ-001, NCT06245213 ). The study has enrolled a total of 71 participants, with 16 participants in Part A and 55 participants in Part B.
- 05/01/2025
|
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
- NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM (ET) on Wednesday, May 7th, 2025.
- 04/30/2025
|
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
- NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board.
- 04/23/2025
|
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
- NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, “Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial” at the 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East.
- 04/21/2025
|
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
- ATTENTION-AD trial data through 192 weeks presented at AD/PD TM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer's disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients. ATTENTION-AD (ANAVEX®2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference.
- 04/05/2025
|
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
- NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:45 PM (ET) on Monday, April 7th, 2025.
- 03/31/2025
|
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
- NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in Boston, MA.
- 02/24/2025
|
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
- Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses.
- 02/14/2025
|
Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025
- Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031. AVXL has top-line data from the ongoing phase 2 study, using blarcamesine for the treatment of patients with Schizophrenia, expected to be released in 2025.
- 02/12/2025
|
Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
- 02/12/2025
|
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
- Company to host a webcast t oday at 8:30 a.m. Eastern Time
- 02/12/2025
|
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
- Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET
- 02/05/2025
|
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
- NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818.
- 01/27/2025
|
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
- AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
- 01/24/2025
|
Best Momentum Stocks to Buy for January 21st
- CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
- 01/21/2025
|
New Strong Buy Stocks for January 21st
- CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.
- 01/21/2025
|
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease
- Blarcamesine potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement
- 01/15/2025
|
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients
- Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients. No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good comparative safety profile and no associated neuroimaging adverse events.
- 01/13/2025
|
Playing The Odds Of Anavex Alzheimer's Drug Approval
- The EMA has accepted Anavex's Alzheimer's drug Blarcamesine for evaluation, with a decision expected by December 2025. Blarcamesine shows a 92% likelihood of approval by the EMA, yet investors have not priced in this probability. The drug significantly slows cognitive decline by 36%, providing potentially priceless extra years of lucidity for patients.
- 01/12/2025
|
Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL)
- Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 01/07/2025
|
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th 2025, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 09:00 AM – 09:40 AM (Pacific Time).
- 01/06/2025
|
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?
- Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.
- 12/31/2024
|
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
- Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/30/2024
|
Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision
- Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and functional decline, and an attractive safety profile. The EMA has accepted ANAVEX 2-73's application for early Alzheimer's, potentially leading to a commercial launch in 2025, boosting AVXL's stock. Despite risks like regulatory hurdles, competition, and cash concerns, AVXL's risk-reward profile is appealing for speculative investors as it nears potential approval.
- 12/27/2024
|
Short-Squeeze Target Anavex Life Sciences Gains Traction
- Anavex Life Sciences NASDAQ: AVXL is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling into the rally. Short interest topped 23% at the end of November and is unlikely to have fallen much since because they spiked to a one-year high, showing a high conviction—plenty of fuel for a short squeeze.
- 12/26/2024
|
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
- Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes.
- 12/24/2024
|
Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2024 Earnings Call Transcript December 23, 2024 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Clint Tomlinson Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
- 12/23/2024
|
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
- Company to host a webcast t oday at 8:30 a.m. Eastern Time
- 12/23/2024
|
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease
- Blarcamesine: Potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement
- 12/23/2024
|
What To Expect in the Markets This Week
- Markets will trade on shortened hours during the Christmas holiday week, with all markets closed Wednesday for the holiday, and shortened trading hours on Christmas Eve.
- 12/22/2024
|
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
- Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET
- 12/16/2024
|
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference
- Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced its upcoming presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial at the J.P.
- 12/09/2024
|
North American Morning Briefing : Global Ad Shares -2-
- Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon Closing; To Also Get up to $150M in Contingent Cash Upon Satisfaction of Condition; Proceeds Will Strengthen Balance Sheet and Support Growth Plans in the Vicuña District Expected Major Events for Monday aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 00:01/UK: Nov KPMG and REC UK Report on Jobs 04:30/JPN: Nov Corporate Insolvencies 05:00/JPN: Nov Economy Watchers Survey 07:00/GER: 3Q Labour cost index 15:00/US: Oct Monthly Wholesale Trade 15:00/US: Nov Employment Trends Index 23:50/JPN: Nov Money Stock, Broadly-defined Liquidity All times in GMT. Powered by Kantar Media and Dow Jones. Expected Earnings for Monday Amtech Systems Inc (ASYS) is expected to report $-0.01 for 4Q. Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials is expected to report for 4Q. Braze Inc (BRZE) is expected to report $-0.30 for 3Q. Buckle Inc (BKE) is expected to report. C3.ai Inc (AI) is expected to report $-0.60 for 2Q. Casey's General Stores Inc (CASY) is expected to report $4.25 for 2Q. Centene Corp (CNC) is expected to report for Full year. Digital Ally Inc (DGLY) is expected to report for 3Q. Franklin Resources Inc (BEN) is expected to report. Genasys Inc (GNSS) is expected to report $-0.11 for 4Q. Healthequity Inc (HQY) is expected to report $0.24 for 3Q. MongoDB Inc (MDB) is expected to report $-0.83 for 3Q. NexPoint Diversified Real Estate Trust (NXDT) is expected to report for 3Q. North West Co Inc (NWC.T) is expected to report $0.77 for 3Q. Oil-Dri Corp of America (ODC) is expected to report for 1Q. Oracle Corp (ORCL) is expected to report $1.06 for 2Q. Phreesia Inc (PHR) is expected to report $-0.27 for 3Q. Planet Labs PBC (PL) is expected to report $-0.08 for 3Q. Remark Holdings Inc (MARK) is expected to report $-0.19 for 3Q. Rent the Runway Inc (RENT) is expected to report for 3Q. Smart Share Global Ltd - ADR (EM) is expected to report for 3Q. Talis Biomedical Corp (TLIS) is expected to report for 3Q. Titan Pharmaceuticals Inc (TTNP) is expected to report for 3Q. Toll Brothers Inc (TOL) is expected to report $4.34 for 4Q. Vail Resorts (MTN) is expected to report $-4.96 for 1Q. VersaBank is expected to report $0.29 for 4Q. Webco Industries Inc (WEBC) is expected to report for 1Q. Yext Inc (YEXT) is expected to report $0.06 for 3Q. Powered by Kantar Media and Dow Jones. ANALYST RATINGS ACTIONS Altria Raised to Buy From Neutral by B of A Securities Argan Cut to Market Perform From Market Outperform by CJS Securities Asana Raised to Sector Weight From Underweight by Keybanc Brixmor Property Group Raised to Outperform From Market Perform by BMO Capital Deere & Co Cut to Hold From Buy by Jefferies DocuSign Cut to Reduce From Hold by HSBC Dollar General Raised to Buy From Underperform by B of A Securities Duckhorn Portfolio Cut to Hold From Buy by Jefferies EPAM Systems Raised to Buy From Neutral by Goldman Sachs Fortrea Holdings Cut to Neutral From Outperform by Baird GrafTech International Raised to Neutral From Underweight by JP Morgan Hewlett Packard Ent Raised to Buy From Neutral by Citigroup Kennametal Cut to Hold From Buy by Jefferies Molson Coors Beverage Raised to Buy From Neutral by B of A Securities ONE Gas Cut to Neutral From Buy by Ladenburg Thalmann Paccar Cut to Hold From Buy by Jefferies Peloton Interactive Raised to Neutral From Sell by UBS PJT Partners Raised to Neutral From Sell by UBS PotlatchDeltic Raised to Outperform From Market Perform by BMO Capital ProFrac Holding Cut to Underweight From Neutral by JP Morgan Prologis Cut to Underperform From Market Perform by BMO Capital ProPetro Holding Raised to Neutral From Underweight by JP Morgan Republic Services Raised to Outperform From Market Perform by BMO Capital Robinhood Markets Raised to Buy From Neutral by Goldman Sachs SiteOne Landscape Supply Raised to Buy From Hold by Jefferies Smith & Wesson Brands Cut to Hold From Buy by Craig-Hallum Smith & Wesson Brands Cut to Hold From Buy by Lake Street Timken Raised to Buy From Hold by Jefferies WesBanco Raised to Strong Buy From Outperform by Raymond James Weyerhaeuser Raised to Outperform From Market Perform by BMO Capital This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires 12-09-24 0634ET
- 12/09/2024
|
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
- NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat being held December 4th, 2024 at 3:25pm ET at the 7th Annual Evercore ISI HealthCONx Conference 2024 in Coral Gables, FL.
- 12/02/2024
|
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA
- • First marketing authorization submission for blarcamesine NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced the submission of the blarcamesine (ANAVEX®2-73) MAA (Marketing Authorization Application) to the European Medicines Agency (EMA). The MAA submission is for the treatment of Alzheimer's Disease.
- 11/26/2024
|
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal
- NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced the acceptance of a peer-reviewed manuscript titled, “Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,” in a medical journal with focus on Alzheimer's disease. The publication date is expected around Q4 2024/Q1 2025.
- 11/25/2024
|
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario
- Anavex Life Sciences' stock surged on new Alzheimer's trial data, but the data's inconsistency raises concerns, making the company a Hold rating. Despite some promising cognitive results, the lack of statistical significance in functional endpoints and mixed trial performance cast doubt on EU approval chances. Anavex 2-73 shows better safety compared to anti-amyloid antibodies, which may influence EMA's decision given the unmet medical need in Alzheimer's treatment.
- 11/06/2024
|
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024
- Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today presented new data from the Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, demonstrates pre-specified clinical efficacy through upstream SIGMAR1 activation. Clinical data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis in people with early Alzheimer's disease (AD).
- 10/31/2024
|
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
- Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced encouraging preliminary electroencephalography (EEG) biomarker results from the Part A of the ongoing placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia. Part A of the Phase 2 study ANAVEX®3-71-SZ-001 (NCT06245213), was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX®3-71 90 mg daily, or oral ANAVEX®3-71 180 mg daily for 10 days.
- 10/17/2024
|
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
- NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024 in New York City.
- 09/03/2024
|
Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Tom Bishop - BI Research Soumit Roy - Jones Research Clint Tomlinson Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Third Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
- 08/06/2024
|
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
- Company to host a webcast today at 8:30 a.m. Eastern Time
- 08/06/2024
|
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
- Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET
- 08/01/2024
|
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
- ANAVEX ® 2-73 corrects directly to humans' translatable EEG biomarkers in a model of Fragile X Syndrome (FXS)
- 07/30/2024
|
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
- Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events
- 07/28/2024
|
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024.
- 06/20/2024
|
Anavex Life Sciences Announces Expansion of Leadership Team
- Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare Systems Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare Systems
- 05/22/2024
|
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
- Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/15/2024
|
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
- NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.
- 05/14/2024
|
Anavex Life Sciences Corporation Class Action: Levi & Korsinsky Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL
- NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79635&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2024
|
AVXL LAWSUIT ALERT: Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79634&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2024
|
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ:AVXL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 13, 2024.
- 05/13/2024
|
Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL
- NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79615&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2024
|
Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79590&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2024
|
AVXL LAWSUIT ALERT: Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79481&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2024
|
Investors who lost money on Anavex Life Sciences Corporation (AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL
- NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79472&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2024
|
Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK , May 13, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between June 21, 2021 and January 1, 2024.
- 05/13/2024
|
Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AVXL
- NEW YORK, NY / ACCESSWIRE / May 12, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79412&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2024
|
Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL
- NEW YORK, NY / ACCESSWIRE / May 12, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79352&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2024
|
Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL
- NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79288&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2024
|
Shareholders that lost money on Anavex Life Sciences Corporation (AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79286&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2024
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ:AVXL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 13, 2024.
- 05/10/2024
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On January 2, 2024, Anavex announced results from a Ph.
- 05/10/2024
|
Levi & Korsinsky Reminds Anavex Life Sciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL
- NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79235&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2024
|
Levi & Korsinsky Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL
- NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79229&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL
- NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79159&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2024
|
Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - AVXL
- NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=79155&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2024
|
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
- Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.
- 05/09/2024
|
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
- Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ET Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ET
- 05/02/2024
|
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
- NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference. Christopher U Missling, PhD, President & Chief Executive Officer is scheduled to present at 1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.
- 04/11/2024
|
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
- 03/25/2024
|
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
- NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.
- 02/26/2024
|
Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript
- 02/07/2024
|
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
- Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET
- 02/01/2024
|
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
- GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
- 01/31/2024
|
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 530.7% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/31/2024
|
New Strong Buy Stocks for January 31st
- ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
- 01/31/2024
|
New Strong Buy Stocks for January 26th
- IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
- 01/26/2024
|
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
- Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/24/2024
|
New Strong Buy Stocks for January 24th
- ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.
- 01/24/2024
|
Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions
- Anavex (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 01/09/2024
|
5 Small-Cap Stocks to Play the January Effect
- Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
- 01/08/2024
|
Anavex Life Sciences shares tank on Rett Syndrome trial results but analysts remain positive
- Anavex Life Sciences (NASDAQ:AVXL) shares plunged this week on mixed results from its Rett Syndrome clinical study but analysts at Dawson James still see the stock as a worthwhile investment. The company reported topline results from its Phase 2/3 EXCELLENCE study in pediatric Rett Syndrome which had enrolled 92 patients aged from five to 17 years.
- 01/04/2024
|
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Anavex's President and Chief Executive Officer, Christopher U Missling, PhD, is scheduled to present at the conference at the Westin St. Francis in San Francisco, CA on January 11, 2024 at 10:30am Pacific Standard Time (PST).
- 01/03/2024
|
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
- The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.
- 12/20/2023
|
Alzheimer's Disease Drug Development: Another Lost Year
- Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.
- 12/05/2023
|
Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2023 Earnings Call Transcript November 27, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Tom Bishop - Bishop Research Operator Good morning, and welcome to the Anavex Life Sciences Fiscal 2023 Fourth Quarter Conference Call. My name is Clint Tomlinson and I will be your host for today's call.
- 11/27/2023
|
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
- Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ET Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ET
- 11/24/2023
|
Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug
- Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.
- 11/21/2023
|
Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors
- Anavex's Alzheimer's drug Blarcamesine demonstrates strong statistical significance in improving cognition among dementia patients as measured by one co-primary endpoint and one secondary endpoint. For the other co-primary endpoint, it seems the drug may not demonstrate statistical significance using Least-Squares Mean methodology. Most recently published data shows Anavex's drug demonstrated statistical significance in manipulating crucial biomarkers: preservation of brain mass and lowering amyloid accumulation.
- 11/13/2023
|
Anavex: The September Data
- Anavex Life Sciences Corp. presented follow-on data from its Alzheimer's disease trial. This data uses a statistical methodology that is difficult to understand. It appears that the trial, despite the claims, was not successful.
- 10/09/2023
|
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
- NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023.
- 08/02/2023
|
Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
- Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET
- 08/01/2023
|
Anavex: Will Be An Interesting Endgame To Watch
- Not much has happened at Anavex Life Sciences Corp. since my last coverage in March. There are a few pieces of news, which I cover here. The toplining of their pivotal trials will be an endgame I will keenly watch.
- 07/18/2023
|
Anavex Life Sciences' Rett syndrome treatment impresses analysts
- Anavex Life Sciences (NASDAQ:AVXL) Corp announced earlier this week that its Rett syndrome treatment showed a disease-modifying effect in a long-term clinical trial. On news of the results, analysts at Dawson James Securities reiterated its Buy rating for the company and its price target of $39.
- 06/30/2023
|
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
- NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference taking place on June 26, 2023.
- 06/20/2023
|
Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year?
- Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
- 06/08/2023
|
Anavex's Blarcamesine: Sigma-1 Receptor Agonists And Antioxidants For Alzheimer's Disease
- Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer's disease. If granted accelerated approval by the FDA, Anavex's stock value is expected to rise significantly. Anavex may provide the best investment opportunity and drug hope for the near long-term stabilization of mild Alzheimer's disease in those with functioning sigma-1 receptors.
- 06/06/2023
|
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/31/2023
|
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 342.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/15/2023
|
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
- Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET
- 05/02/2023
|
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
- NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.
- 04/25/2023
|
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
- NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other Central Nervous System (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the 22nd Annual Needham Virtual Healthcare Conference 2023 on Monday, April 17, 2023, at 8:00 AM ET.
- 04/10/2023
|
Buy Anavex For Its Likely Positive Alzheimer's Disease Data
- The ANAVEX2-73-AD-004 trial was mostly positive. A reputable journal article on the missing data would allay fears of a 'spin'.
- 03/16/2023
|
Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing Well
- Anavex seems to have effectively handled the Rett syndrome endpoint issues. A future publication should also throw more light on the AD data.
- 03/08/2023
|
Why Shares of Anavex Life Sciences Rose 12.4% in February
- Anavex is a clinical-stage biotech stock with no revenue. The company's lead therapy is being tested to treat a host of neurodegenerative and neurological conditions.
- 03/06/2023
|
Is Anavex Life Sciences Stock a Buy Now?
- A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
- 02/23/2023
|
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
- Short-sellers have piled into this clinical-stage biopharma stock.
- 02/09/2023
|
Anavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDA
- Anavex Life Sciences recently reported their Q1 2023 earnings that revealed a beat on EPS and a robust cash position that should fund the company for the next four years. The company updated investors on ANAVEX 2-73 in Alzheimer's and publicized that they “plan to submit the data for publication and peer-reviewed medical journal in the near term”.
- 02/09/2023
|
Why Anavex Life Sciences Stock Bolted Higher in January
- The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
- 02/08/2023
|
Anavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Yun Zhong - BTIG Clint Tomlinson Good morning, everyone. And welcome to the Anavex Life Sciences' Fiscal 2023 First Quarter Conference Call.
- 02/07/2023
|
Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved
- FDA grants emergency approval of Biogen/Eisai's Leqembi (previously Lecanemab), based solely on Phase 2 trial results; Phase 3 results to be considered for final approval. Anavex Life Sciences produces the alternative Alzheimer's drug Blarcamesine, which appears more effective, cheaper and safer than Leqembi, based on Blarcamesine's Phase 2b/3 trial.
- 01/30/2023
|
3 Biotech Stocks Under $15 Worth a Second Look in 2023
- All three stocks have promising therapies that could drive revenue in the coming years.
- 01/18/2023
|
Anavex: Drug Treatments For Early Alzheimer's Disease
- Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon's ALZ-801 reduces cognitive decline in ApoE4 carriers by about the same amount as Eisai and Biogen's Leqembi and Aduhelm, but without the risks of brain bleeds and swelling.
- 01/17/2023
|
Anavex: Despite Positive Spin, No Clarity On Anomalies
- Anavex Life Sciences Corp. presented solid-looking Alzheimer's data last month. Critics found a number of anomalies, some more real than others.
- 01/12/2023
|
6 Favorite Biotech Bets For 2023
- Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
- 01/09/2023
|
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
- The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
- 12/17/2022
|
Is Anavex Life Sciences a Buy?
- It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
- 12/13/2022
|
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
- NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th 2023, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 08:15 AM - 08:55 AM (Pacific Time).
- 12/12/2022
|
Anavex Life Sciences: The Little Company That Did
- Anavex's 2-73/blarcamesine produced significant reductions in cognitive decline in early Alzheimer's disease as measured by ADAS-Cog and CDR-SB scores. Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically significant.
- 12/06/2022
|
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
- Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
- 12/05/2022
|
Is Anavex Life Sciences a Smart Stock to Buy Now?
- The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it?
- 12/03/2022
|
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
- Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET
- 12/02/2022
|
Why Anavex Life Sciences Stock Is Surging Today
- The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate.
- 12/02/2022
|
Biotech Stock Blasts Higher on Upbeat Trial Data
- Anavex Life Sciences Corp (NASDAQ:AVXL) is surging up 26.8% at $11.25 at last glance, and was earlier trading as high as $12.73.
- 12/02/2022
|
Why Is Anavex Life Sciences (AVXL) Stock Up 30% Today?
- Anavex Life Sciences (NASDAQ: AVXL ) stock is rocketing higher on Friday following positive results from a clinical trial. The results come from its Phase 2b/3 clinical trial of ANAVEX®2-73.
- 12/02/2022
|
Anavex Catapults On Alzheimer's Results — But Math Question Clouds The Data
- Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday. The post Anavex Catapults On Alzheimer's Results — But Math Question Clouds The Data appeared first on Investor's Business Daily.
- 12/02/2022
|
Why Shares of Anavex Life Sciences Slumped 23.5% on Monday
- The company released its fiscal fourth-quarter and full-year numbers.
- 11/28/2022
|
Anavex Life Sciences Corp. (AVXL) Q4 2022 Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2022 Earnings Conference Call November 28, 2022 8:30 AM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Soumit Roy - Jones Trading Yun Zhong - BTIG Clint Tomlinson Welcome to the Anavex Life Sciences' Fiscal 2022 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I'll be your host for today's call.
- 11/28/2022
|
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
- Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET
- 11/23/2022
|
Anavex Life Sciences At A Pivotal Moment
- Anavex will present results from its phase 2b/3 trial for blarcamesine for Alzheimer's disease at the CTAD conference in San Francisco on December 1st. A past trial suggests that Anavex's blarcamesine modifies mild Alzheimer's disease in some patients at 148 weeks.
- 11/08/2022
|
Trading Ideas On The Upcoming CTAD 2022 Conference
- The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
- 11/02/2022
|
Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
- Anavex has two big catalysts coming up, both in Alzheimer's disease and Parkinson's Disease Dementia. Results reported so far show long-lasting cognition changes, and I am expecting Anavex to report improvement in cognition of patients on the upcoming trial readout.
- 09/19/2022
|
Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
- Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (blarcamesine, Trappsol Cyclo, panax ginseng) that inhibit the formation of peroxynitrite, scavenge it, and reverse part of its damage largely stabilize Alzheimer's disease for long periods of time.
- 09/07/2022
|
Anavex And The Debunking Of The Amyloid Hypothesis
- Recent research is claiming pivotal study data was falsified in order to bolster the amyloid hypothesis. This should have a positive impact on Alzheimer's programs based on other mechanisms.
- 08/11/2022
|
Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2022 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Yun Zhong - BTIG Raghuram Selvaraju - H.C. Wainwright Clint Tomlinson Good afternoon.
- 08/09/2022
|
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
- Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET
- 08/03/2022
|
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/13/2022
|
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 238%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 06/27/2022
|
Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease
- Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release.
- 06/02/2022
|
Anavex: Increasing Shareholder Value Against All Odds
- As the recent Rett syndrome controversy shows, Anavex is a perpetually beleaguered stock. Despite the tremendous bearish headwind it always faces, the company has been able to increase shareholder value over the years.
- 05/31/2022
|
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/25/2022
|
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
- NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the H. C. Wainwright Global Investment Conference 2022 on Wednesday, May 25, 2022, at 12:00 PM ET.
- 05/19/2022
|
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer. Conference Call Participants Yun Zhong - BTIG Pete Stavropoulos - Cantor Operator Welcome to the Anavex Life Sciences Fiscal 2022 Second Quarter Conference Call.
- 05/10/2022
|
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
- Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET
- 05/03/2022
|
Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
- NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022, at 11:00 AM ET.
- 04/26/2022
|
Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
- NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Anavex Management Team will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 3:45 PM ET.
- 04/07/2022
|
Make Biotech Cash Considerations With SBIO
- In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies.
- 03/28/2022
|
Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
- Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptors. Simufilam may do the same.
- 03/22/2022
|
Anavex Life Sciences Highlights Biomarker Data From Parkinson's Disease Dementia At International Conference
- Anavex Life Sciences Corp (NASDAQ: AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for.
- 03/15/2022
|
Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
- NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference and present on Wednesday, February 16 at 3 pm ET.
- 02/10/2022
|
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2022 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2022 Results - Earnings Call Transcript
- 02/09/2022
|
Anavex: The First Impression May Not Be The Right Impression
- AVXL reported positive topline data from their trial for Rett syndrome in adults on Feb 1, 2022. However, the results were met with much skepticism or cynicism, due to changes to the trial's endpoints, registered on the clinicaltrials.gov site that was submitted on Jan 18.
- 02/03/2022
|
Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022
- Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET
- 02/03/2022
|
Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
- Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
- 02/01/2022
|
Anavex Life Sciences (AVXL) Stock: Why The Price Substantially Fell Today
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) fell by over 13% during intraday trading today. This is why it happened.
- 02/01/2022
|
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals
- Anavex Life Sciences Corp AVXL reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ultimate Bear Market Survival Guide with Matt Maley!
- 02/01/2022
|
Anavex: 2022 Has Major, Pivotal Catalysts
- Anavex's long story is coming to a climax this year. The company will announce topline data from the Alzheimer's trial by 2H 2022.
- 01/17/2022
|
Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study
- Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including Frontotemporal Dementia (FTD). ANAVEX3-71 was well tolerated in all cohorts receiving single doses of the treatment candidate ranging from 5 mg to 200 mg daily with no serious adverse events (SAEs) and no significant lab abnormalities in any subject.
- 01/10/2022
|
Anti-Amyloid Drugs: The Failure Of Success
- Anti-Amyloid Drugs: The Failure Of Success
- 01/01/2022
|
Is the Options Market Predicting a Spike in Anavex (AVXL) Stock?
- Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.
- 12/29/2021
|
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
- Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time
- 12/14/2021
|
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
- NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021 at 12:10 p.m. ET.
- 11/29/2021
|
Is it safe to buy Anavex shares after matching earnings expectations?
- On Wednesday, Anavex Life Sciences Corp (NASDAQ:AVXL) shares rallied 5.68% after reporting its most recent annual results. The company announced its full-year 2021 results before markets opened, matching the consensus expectations on earnings.
- 11/25/2021
|
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q4 2021 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q4 2021 Results - Earnings Call Transcript
- 11/24/2021
|
Earnings Outlook For Anavex Life Sciences
- Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.
- 11/23/2021
|
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
- Webcast and Conference Call To be Held Wednesday November 24, 2021, 4:30 pm EDT Webcast and Conference Call To be Held Wednesday November 24, 2021, 4:30 pm EDT
- 11/17/2021
|
An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
- An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
- 11/10/2021
|
Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?
- Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
- 11/05/2021
|
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
- Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed.
- 10/16/2021
|
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
- NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the Dawson James Securities 6th Annual Conference on Thursday, October 21, 2021 at 1:30 PM (ET).
- 10/15/2021
|
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
- NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Fragile X Syndrome Case Study: From Preclinical to Clinical, Making Drug Development Efficient through Community-based Collaboration” at the 5th Pharma Pricing, Reimbursement & Market Access 2021 conference on Wednesday, September 29th at 2:40 pm ET.
- 09/27/2021
|
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
- NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that effective as of market open today, September 27, 2021, its shares of common stock have been approved for uplisting to the NASDAQ Global Select Market® and will continue trading under its current ticker symbol AVXL.
- 09/27/2021
|
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
- NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:40 AM (ET). The conference is being held September 27-30, 2021.
- 09/20/2021
|
Anavex Life Sciences: Still Room To Run
- Lead candidate ANAVEX2-73 has shown impressive results in placebo-controlled Phase 2 studies in Parkinson's disease and Rett syndrome. Ongoing studies in Rett syndrome could lead to a filing in 2022 if results are positive.
- 08/29/2021
|
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
- NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2021.
- 08/12/2021
|
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
- NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 9:30 a.m. EDT.
- 08/04/2021
|
Detours In The Golden Age Of Alzheimer's Drug Stock Investments
- Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.
- 08/03/2021
|
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
- A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
- 07/29/2021
|
Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study
- Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with blarcamesine repeated once daily for one week before the Aβ (Abeta) challenge was protective in the Aβ25-35 peptide model of Alzheimer's mice model.
- 07/29/2021
|
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
- On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
- 07/27/2021
|
3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021
- Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/21/2021
|
Anavex: A Catalyst-Rich Year
- Anavex Life Sciences Corporation conducts clinical trials for its small Anavex 2-73 (blarcamesine) and Anavex 3-71 (AF710B) molecules. The biotech has a rich development pipeline aimed at neurodegenerative and neuro-developmental disorders, such as Parkinson's, Alzheimer's and Rett diseases.
- 07/05/2021
|
Why This Anavex Life Sciences Analyst Is Lifting Their Price Target
- A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ:AVXL) after the release of Phase 2 data for the company's lead candidate. The Anavex Analyst: Charles Duncan, Ph.D.
- 06/28/2021
|
AVXL Stock Price Increases Over 15%: Why It Happened
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) increased by over 15% during intraday trading. This is why it happened.
- 06/28/2021
|
Anavex Life Sciences Stock Rallies: Technical Levels To Watch
- Anavex Life Sciences Corp. (NASDAQ: AVXL) shares traded higher Monday after the company announced ANAVEX2-73, the company's main pipeline drug, improved both primary cognitive and secondary MDS-UPDRS efficacy endpoints with significant biomarker correlation in placebo-controlled Phase 2 clinical trial for treatment of Parkinson's disease. Anavex Life Sciences was up 18.37% at $29.30 at last check.
- 06/28/2021
|
7 Hot Penny Stocks Analysts Like To Watch In 2021
- Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/28/2021
|
Why Anavex Life Sciences Shares Are Up 17% Today
- The biopharma developer dropped some big (but mostly expected) news about the success of one of its drugs.
- 06/28/2021
|
Anavex Life Sciences Stock Jumps As Blarcamesine Shows Convincing Biomarker-Correlating Efficacy Data In Parkinson's Disease, Dementia Patients
- Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 (blarcamesine) in patients with Parkinson's disease dementia. ANAVEX 2-73 activates the sigma-1 receptor (SIGMAR1), restoring neural cell homeostasis and promoting neuroplasticity.
- 06/28/2021
|
3 Top Biotech Stocks to Buy Right Now
- These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.
- 06/26/2021
|
Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering
- NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct offering to Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock at a purchase price of $21.00 per share of common stock. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
- 06/24/2021
|
AVXL Stock Price Falls Over 5% Pre-Market: Why It Happened
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) fell by over 5% pre-market. This is why it happened.
- 06/22/2021
|
Why Anavex Life Sciences Blasted Higher Today
- The good news keeps coming for one of the biotech's pipeline drugs.
- 06/21/2021
|
AVXL Stock Price Increases Over 10% Pre-Market: Why It Happened
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) increased by over 10% pre-market. This is why it happened.
- 06/21/2021
|
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
- ANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints RSBQ (p = 0.035) and CGI-I (p = 0.029)
- 06/21/2021
|
Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options
- Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.
- 06/18/2021
|
AVXL Stock Price Increased 35.42%: Why It Happened
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) increased by 35.42% yesterday. This is why it happened.
- 06/15/2021
|
Why Anavex Life Sciences Stock Soared 35% Today
- Research published in a medical journal provides enormous hope for the company's pipeline Alzheimer's drug.
- 06/14/2021
|
Why Anavex Shares Are Surging Today
- Anavex Life Sciences Corp (NASDAQ:AVXL) shares are trading higher by 25.7% at $19.49 after the company highlighted ANAVEX 2-73 and ANAVEX3-71 for Alzheimer's were featured in the journal of Expert Opinion on Therapeutic Targets. Read more here… Anavex Life Sciences is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need.
- 06/14/2021
|
AVXL Stock Price: Over 9% Increase Details
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) increased by over 9% during intraday trading. These are the details.
- 06/14/2021
|
Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease
- NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today reported that ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets , titled “The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer's”.1
- 06/14/2021
|
Anavex Life Sciences (AVXL) Just Reclaimed the 50-Day Moving Average
- Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
- 06/03/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2021 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season
- Anavex Life Sciences (AVXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/11/2021
|
Anavex Life Sciences to Present at the B. Riley Securities' Virtual Neuroscience Conference
- NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the B. Riley Securities' Virtual Neuroscience Conference on Wednesday, April 28, 2021 at 12:00 p.m. EDT.
- 04/26/2021
|
3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases
- 3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases
- 04/16/2021
|
Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference
- NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 8:45 a.m. EDT.
- 04/08/2021
|
Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021
- NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Establishing Mutually Beneficial Collaborations,” at the World EPA Congress 2021 event on Thursday, April 15t h at 8:55 a.m. EDT (14:55 CET).
- 04/07/2021
|
Anavex: Small Company Targeting The Holy Grail Of Medicine
- Anavex is targeting Alzheimer's disease and other neurodegenerative diseases. It recently announced positive data from two of its programs.
- 04/06/2021
|
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer's Disease
- NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Independent Data Safety Monitoring Board (DSMB) for the Company's Phase 2b/3 Alzheimer's disease study of its investigational compound ANAVEX®2-73 (blarcamesine) has completed its recent pre-planned review of the preliminary Phase 2b/3 study data.
- 03/31/2021
|
Anavex And Cassava Sciences: Closer To An Understanding Of Alzheimer's Disease
- Cassava Sciences simufilam produced an improvement in ADAS-cog scores of 1.6 points at 6 months.
- 03/23/2021
|
Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
- NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021.
- 03/04/2021
|
Top Wall Street analysts say buy stocks like Denny's and Cloudflare as economy reopens
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Shopify & GoDaddy
- 02/21/2021
|
Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021
- NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, has been invited to present at the 10 th Annual SVB Leerink Global Healthcare Conference.
- 02/18/2021
|
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2021 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2021 Results - Earnings Call Transcript
- 02/12/2021
|
Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook
- Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET
- 02/11/2021
|
Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021
- Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time
- 02/08/2021
|
AVXL Stock Price Increases Over 60% Pre-Market: Why It Happened
- The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) is trading at over 60% pre-market today as of 6:04 AM ET. This is why it happened.
- 02/04/2021
|
Biotech Bonanza: COVID Launches Science at Warp Speed
- From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
- 02/03/2021
|
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73
- Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers.
- 01/22/2021
|
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference
- NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.
- 01/06/2021
|
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's Why
- Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/31/2020
|
Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript
- Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript
- 12/28/2020
|
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates
- Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET
- 12/28/2020
|
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020
- Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time
- 12/22/2020
|
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.
- NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Ladenburg Thalmann & Co. will host a webinar at 3:30p.m. Eastern Time on Tuesday, December 22nd, 2020 highlighting Rett Syndrome and ANAVEX®2-73 (blarcamesine) Phase 2 data as part of Ladenburg Thalmann's LT Healthcare Symposia Series.
- 12/21/2020
|
Why Anavex Life Sciences Stock Jumped Today
- The company reported positive results from a phase 2 clinical trial.
- 12/15/2020
|
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
- Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I
- 12/15/2020
|
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders
- Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio
- 11/30/2020
|
Where Do Hedge Funds Stand On Anavex Life Sciences Corp. (AVXL)?
- The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As a result, the relevancy of these public filings and their content is indisputable, as they may reveal numerous high-potential stocks. The following article will discuss the smart money sentiment towards Anavex Life Sciences Corp. (NASDAQ:AVXL).
- 11/27/2020
|
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
- NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 11:45 a.m. ET.
- 11/25/2020
|
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson's Disease Dementia Presented at CTAD 2020 Conference
- Statistically s ignificant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008)
- 11/06/2020
|
Alfa SAB de CV (ALFFF) CEO on Q3 2020 Results - Earnings Call Transcript
- Alfa SAB de CV (OTCPK:ALFFF) Q3 2020 Earnings Conference Call October 22, 2020, 13:00 ET Company Participants Hernan Lozano - VP, IR & Corporate Communications Eduardo Escalante - CFO Roberto Olivares - CFO, Sigma Alberto Sada - CFO Carlos Jiménez Barrera - Senior VP of Legal, Audit & Corporate Affairs and Secretary Conference Call Participants Vanessa Quiroga - Crédit Suisse Nikolaj Lippmann - Morgan Stanley Eric Neguelouart - Bank of America Merrill Lynch Alejandro Azar - GBM Alfonso Salazar - Scotiabank Gilberto Garcia - Barclays Bank Jean Bruny - BBVA Andres Cardona - Citigroup Manuela Echavarría - Credicorp Capital Alejandro Chavelas - Crédit Suisse Presentation Operator Greetings, and welcome to ALFA's Third Quarter 2020 Earnings Conference Call.
- 10/23/2020
|
12 Technology Stocks Moving In Thursday's After-Market Session
- Gainers
Socket Mobile (NASDAQ:SCKT) shares moved upwards by 60.27% to $2.34 during Thursday's after-market session. Today's trading volume for this security ended up...
- 10/22/2020
|
Worldwide Bicycle Infotainment System Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com
|
Proteostasis Therapeutics (NASDAQ:PTI) Upgraded by Zacks Investment Research to Buy
- Zacks Investment Research upgraded shares of Proteostasis Therapeutics (NASDAQ:PTI) from a hold rating to a buy rating in a research note released on Saturday morning, Zacks.com reports. The firm currently has $1.25 price objective on the stock. According to Zacks, “Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of […]
- 10/20/2020
|
Campbell & CO Investment Adviser LLC Makes New Investment in Hecla Mining (NYSE:HL)
- Campbell & CO Investment Adviser LLC acquired a new position in Hecla Mining (NYSE:HL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,800 shares of the basic materials company’s stock, valued at approximately $80,000. A number of other hedge […]
- 10/19/2020
|
Gladstone Investment Co. (NASDAQ:GAIN) Given Average Recommendation of “Hold” by Analysts
- Shares of Gladstone Investment Co. (NASDAQ:GAIN) have been given a consensus recommendation of “Hold” by the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 12-month target price among brokers […]
- 10/17/2020
|
Tiaa Fsb Cuts Stock Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG)
- Tiaa Fsb decreased its position in shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) by 8.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,996 shares of the company’s stock after selling 4,427 shares during the period. Tiaa Fsb’s holdings in Vanguard Dividend […]
- 10/15/2020
|
UK Regulatory Announcement: Company Announcement
- For Immediate Release 15 October 2020 COMPANY ANNOUNCEMENT SIGMA FINANCE CORPORATION (IN RECEIVERSHIP) The receivers of Sigma Finance Corporation (I
- 10/15/2020
|
How Low-Profile VC Firm Sutter Hill Lands Big Exits
- While it’s definitely not one of the Silicon Valley VC firms vying for headlines, Sutter Hill Ventures' power player status lies in its record and its reputation.
- 10/14/2020
|
Envestnet Asset Management Inc. Purchases 66,684 Shares of Xcel Energy Inc (NYSE:XEL)
- Envestnet Asset Management Inc. lifted its position in Xcel Energy Inc (NYSE:XEL) by 19.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 410,822 shares of the utilities provider’s stock after purchasing an additional 66,684 shares during the period. Envestnet […]
- 10/14/2020
|
Global Retirement Partners LLC Reduces Stock Holdings in Invesco S&P 500 Low Volatility ETF (NYSEARCA:SPLV)
- Global Retirement Partners LLC lessened its holdings in shares of Invesco S&P 500 Low Volatility ETF (NYSEARCA:SPLV) by 69.9% in the third quarter, Holdings Channel.com reports. The firm owned 772 shares of the company’s stock after selling 1,794 shares during the period. Global Retirement Partners LLC’s holdings in Invesco S&P 500 Low Volatility ETF were […]
- 10/14/2020
|
Gran Tierra Energy Inc (NYSEAMERICAN:GTE) Major Shareholder Gmt Capital Corp Sells 2,633,897 Shares of Stock
- Gran Tierra Energy Inc (NYSEAMERICAN:GTE) major shareholder Gmt Capital Corp sold 2,633,897 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $0.23, for a total transaction of $605,796.31. Following the completion of the sale, the insider now directly owns 78,425,879 shares of the company’s […]
- 10/14/2020
|
Sigma Helps Yesware’s Marketing Team Make Data the Driver Behind Every Decision
- Sigma Computing, an innovator in cloud analytics and business intelligence for enterprise teams, has helped Yesware achieve its goal to become 100 per
- 10/13/2020
|
Precision Drilling (NYSE:PDS) Stock Rating Upgraded by Atb Cap Markets
- Atb Cap Markets upgraded shares of Precision Drilling (NYSE:PDS) (TSE:PD) from a sector perform rating to an outperform rating in a report released on Wednesday, Zacks.com reports. A number of other equities analysts have also recently issued reports on the company. BMO Capital Markets increased their target price on Precision Drilling from $1.00 to $1.25 […]
- 10/11/2020
|
State of Alaska Department of Revenue Has $3.96 Million Stock Holdings in Stamps.com Inc. (NASDAQ:STMP)
- State of Alaska Department of Revenue lifted its stake in shares of Stamps.com Inc. (NASDAQ:STMP) by 7.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 16,436 shares of the software maker’s stock after buying an additional 1,130 shares during the quarter. State of Alaska Department of Revenue’s holdings in Stamps.com were worth $3,960,000 […]
- 10/10/2020
|
Two Sigma Advisers LP Boosts Holdings in Innoviva, Inc. (NASDAQ:INVA)
- Two Sigma Advisers LP increased its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 74.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,634 shares of the biotechnology company’s stock after purchasing an additional 20,800 shares during the period. Two […]
- 10/08/2020
|
MCCORMICK & CO /SH NV (NYSE:MKC) Shares Sold by Private Trust Co. NA
- Private Trust Co. NA reduced its position in MCCORMICK & CO /SH NV (NYSE:MKC) by 71.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,467 shares of the company’s stock after selling 3,691 shares during the quarter. Private Trust Co. NA’s holdings in MCCORMICK & CO /SH were worth $284,000 as of its […]
- 10/03/2020
|
Two Sigma Advisers LP Cuts Stock Holdings in Sinclair Broadcast Group Inc (NASDAQ:SBGI)
- Two Sigma Advisers LP trimmed its position in shares of Sinclair Broadcast Group Inc (NASDAQ:SBGI) by 30.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,250 shares of the company’s stock after selling 38,300 shares during the quarter. Two […]
- 10/03/2020
|
Two Sigma Advisers LP Cuts Stock Holdings in Pitney Bowes Inc. (NYSE:PBI)
- Two Sigma Advisers LP trimmed its position in shares of Pitney Bowes Inc. (NYSE:PBI) by 9.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 702,900 shares of the technology company’s stock after selling 72,700 shares during the quarter. Two Sigma Advisers LP owned […]
- 10/02/2020
|
Engineers Gate Manager LP Acquires 12,800 Shares of Callon Petroleum (NYSE:CPE)
- Engineers Gate Manager LP increased its holdings in Callon Petroleum (NYSE:CPE) by 29.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,621 shares of the oil and natural gas company’s stock after buying an additional 12,800 shares during the period. Engineers Gate Manager […]
- 10/02/2020
|
Altius 3rd Quarter Project Generation Business Update
- Altius Minerals Corp. (ALS:TSX) (ATUSF:OTCQX) (“Altius”) provides an update on its project generation (PG) business activities and the performance of
- 10/02/2020
|
Sigma Announces the 105mm F2.8 DG DN Macro | Art Lens, Redefining Mirrorless Macro Performance
- Life-sized magnification (1:1) short tele macro for full-frame mirrorless
Dust and Splash-proof construction
Completely new optical formula for exceptional
- 09/30/2020
|
Nuveen Asset Management LLC Increases Stake in Tripadvisor Inc (NASDAQ:TRIP)
- Nuveen Asset Management LLC boosted its stake in Tripadvisor Inc (NASDAQ:TRIP) by 27.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 749,248 shares of the travel company’s stock after buying an additional 159,541 shares during the period. Nuveen Asset Management LLC owned 0.56% […]
- 09/30/2020
|
Ingevity Corp (NYSE:NGVT) Shares Bought by Nuveen Asset Management LLC
- Nuveen Asset Management LLC grew its holdings in Ingevity Corp (NYSE:NGVT) by 10.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 264,784 shares of the company’s stock after purchasing an additional 25,179 shares during the period. Nuveen Asset Management LLC […]
- 09/30/2020
|
Schonfeld Strategic Advisors LLC Invests $141,000 in Matador Resources Co (NYSE:MTDR)
- Schonfeld Strategic Advisors LLC acquired a new position in shares of Matador Resources Co (NYSE:MTDR) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,600 shares of the energy company’s stock, valued at approximately $141,000. Several other institutional investors and hedge funds have […]
- 09/29/2020
|
Lithium Junior Miner News For The Month Of September 2020
- Lithium prices were mixed for the month but remain low. Lithium market news - EU sounds alarmed on critical raw materials shortages - needs 18x more lithium by 2030, 60x by 2050.
- 09/28/2020
|
Precision Drilling Corp Expected to Post FY2020 Earnings of ($0.39) Per Share (NYSE:PDS)
- Precision Drilling Corp (NYSE:PDS) (TSE:PD) – Raymond James raised their FY2020 earnings per share estimates for Precision Drilling in a report issued on Wednesday, September 23rd. Raymond James analyst A. Bradford now anticipates that the oil and gas company will earn ($0.39) per share for the year, up from their previous forecast of ($0.41). Raymond […]
- 09/28/2020
|
Fact check: Two Sigma is not owned by George Soros
- Thousands of social media users are sharing posts that claim Fox News and Fox Business Network anchor Melissa Francis silenced former Republican House of Representatives Speaker Newt Gingrich, when he was talking on air about George Soros because Francis’ husband works for...
- 09/24/2020
|
Bank of Montreal Can Has $243,000 Stock Holdings in Cinemark Holdings, Inc. (NYSE:CNK)
- Bank of Montreal Can raised its stake in shares of Cinemark Holdings, Inc. (NYSE:CNK) by 233.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,978 shares of the company’s stock after purchasing an additional 13,285 shares during the quarter. Bank of Montreal Can’s […]
- 09/24/2020
|
Jacobs Levy Equity Management Inc. Cuts Stock Position in Matador Resources Co (NYSE:MTDR)
- Jacobs Levy Equity Management Inc. decreased its holdings in shares of Matador Resources Co (NYSE:MTDR) by 61.4% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 27,223 shares of the energy company’s stock after selling 43,298 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Matador […]
- 09/23/2020
|
Campofrío revoluciona la cúpula tras la salida del que fue su histórico presidente
- Los mexicanos de Sigma Alimentación (Grupo Alfa), dueños del 100% de la cárnica, han dado la vuelta al consejo de administración después de la salida definitiva de Pedro Ballvé tras 34 años
- 09/23/2020
|
Global Industrial Packaging Market Analysis 2020-2026, by Product, Material and End-User Vertical - ResearchAndMarkets.com
|
Engineers Gate Manager LP Grows Stake in Benefitfocus Inc (NASDAQ:BNFT)
- Engineers Gate Manager LP raised its holdings in Benefitfocus Inc (NASDAQ:BNFT) by 29.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,167 shares of the software maker’s stock after acquiring an additional 13,116 shares during the period. Engineers Gate Manager […]
- 09/22/2020
|
EU sanctions Turkish firm over Libya arms embargo violations
- The European Union has slapped sanctions on three transport companies for violating the U.N. arms embargo on Libya, including the Turkish shipping firm that operates a vessel at the center of a naval standoff in the Mediterranean Sea
- 09/21/2020
|
Culp, Inc. (NYSE:CULP) Expected to Announce Earnings of $0.15 Per Share
- Wall Street analysts expect that Culp, Inc. (NYSE:CULP) will post $0.15 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Culp’s earnings. The lowest EPS estimate is $0.12 and the highest is $0.17. Culp posted earnings per share of $0.19 in the same quarter last year, which […]
- 09/20/2020
|
Bank of New York Mellon Corp Has $11.15 Million Stock Holdings in NOW Inc (NYSE:DNOW)
- Bank of New York Mellon Corp decreased its position in shares of NOW Inc (NYSE:DNOW) by 2.1% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,292,098 shares of the oil and gas company’s stock after selling 27,858 shares during the period. Bank of New York Mellon Corp’s holdings in NOW were worth $11,151,000 at […]
- 09/17/2020
|
Sigma Computing Hires First Chief Revenue Officer Amidst Rapid Growth
- Sigma Computing, an innovator in cloud-native analytics and business intelligence (ABI), announced today the appointment of seasoned sales leader Mark
- 09/17/2020
|
Global Configure Price and Quote (CPQ) Software Market- Featuring Accenture Plc, Apttus Corp., and Aspire Technologies Inc. Among Others
- The Global Configure Price And Quote (CPQ) Software Market will grow by USD 1.14 bn during 2020-2024
- 09/16/2020
|
Athenex Inc (NASDAQ:ATNX) Major Shareholder Perceptive Advisors Llc Acquires 200,000 Shares
- Athenex Inc (NASDAQ:ATNX) major shareholder Perceptive Advisors Llc bought 200,000 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were acquired at an average price of $11.24 per share, for a total transaction of $2,248,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […]
- 09/15/2020
|
Satsuma Migraine Failure, And Other News: The Good, Bad And Ugly Of Biopharma
- Satsuma reports disappointing top-line data for Phase 3 trial. Ocular Therapeutix begins dosing for Dextenza study.
- 09/14/2020
|
Nokia Oyj (NYSE:NOK) Shares Acquired by Advisory Services Network LLC
- Advisory Services Network LLC lifted its holdings in shares of Nokia Oyj (NYSE:NOK) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 99,381 shares of the technology company’s stock after buying an additional 10,449 shares during the period. Advisory Services Network LLC’s holdings in […]
- 08/28/2020
|
Global Apoptosis Assays Industry (2020 to 2026) - Products, Detection Technologies, Applications and End-use Markets - ResearchAndMarkets.com
|
Sigma Computing Helps Digital Manufacturing Trailblazer Shatter Data Literacy Barriers, Lower Costs, and Increase Customer Satisfaction
- Sigma Computing, an innovator in cloud analytics and business intelligence (A&BI) for enterprise teams, is helping Fictiv disrupt the manufacturin
- 08/27/2020
|
Teza Capital Management LLC Purchases Shares of 24,491 Cinemark Holdings, Inc. (NYSE:CNK)
- Teza Capital Management LLC purchased a new stake in Cinemark Holdings, Inc. (NYSE:CNK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,491 shares of the company’s stock, valued at approximately $283,000. Several other hedge funds and other institutional investors […]
- 08/26/2020
|
Invest Through Your IRA into Alpha Sigma Capital's Digital Asset Fund
- (via Blockchain Wire) Alpha Sigma Capital (ASC), a pioneering digital asset fund investing in emerging cryptocurrencies and blockchain companies is now
- 08/26/2020
|
Virtu Financial LLC Takes Position in Callon Petroleum (NYSE:CPE)
- Virtu Financial LLC purchased a new stake in Callon Petroleum (NYSE:CPE) during the second quarter, according to its most recent filing with the SEC. The firm purchased 234,705 shares of the oil and natural gas company’s stock, valued at approximately $270,000. Virtu Financial LLC owned 0.06% of Callon Petroleum at the end of the most […]
- 08/26/2020
|
How to hybrid: Advice from leaders mixing up the world of work
- As hybrid working looks set to become the norm post-Covid, Elaine Burke asks company leaders with experience managing hybrid teams for some best practice advice.
- 08/25/2020
|
Weekly Investment Analysts’ Ratings Updates for SAGE Therapeutics (SAGE)
- A number of research firms have changed their ratings and price targets for SAGE Therapeutics (NASDAQ: SAGE): 8/24/2020 – SAGE Therapeutics had its price target raised by analysts at Morgan Stanley from $85.00 to $87.00. They now have an “overweight” rating on the stock. 8/11/2020 – SAGE Therapeutics had its price target raised by analysts […]
- 08/25/2020
|
Benefitfocus’ (BNFT) Buy Rating Reiterated at Raymond James
- Raymond James reiterated their buy rating on shares of Benefitfocus (NASDAQ:BNFT) in a research report released on Monday, AnalystRatings.com reports. Several other research firms also recently weighed in on BNFT. Piper Sandler lifted their price objective on Benefitfocus from $26.00 to $30.00 and gave the company an overweight rating in a report on Thursday, August […]
- 08/25/2020
|
Sigma Designs (OTCMKTS:SIGM) Stock Passes Above 200-Day Moving Average of $0.23
- Sigma Designs Inc (OTCMKTS:SIGM)’s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.23 and traded as high as $0.29. Sigma Designs shares last traded at $0.28, with a volume of 19,783 shares. The company’s 50-day moving average is […]
- 08/25/2020
|
Sigma Computing Named a 2020 SaaS Awards Winner
- Sigma Computing, an innovator in cloud analytics and business intelligence (A&BI) for enterprise teams, is the SaaS Awards winner for Best SaaS fo
- 08/25/2020
|
Douglas Emmett (NYSE:DEI) PT Lowered to $30.00 at Citigroup
- Douglas Emmett (NYSE:DEI) had its target price cut by equities research analysts at Citigroup from $31.00 to $30.00 in a research report issued to clients and investors on Monday, BenzingaRatingsTable reports. The brokerage currently has a “neutral” rating on the real estate investment trust’s stock. Citigroup‘s price objective would indicate a potential upside of 8.30% […]
- 08/24/2020
|
Sigma Computing Selected as a Bay Area News Group Top Workplace
- Sigma Computing earned a spot on the Bay Area News Group’s esteemed Top Workplaces list. The cloud analytics and business intelligence (A&BI) inno
- 08/24/2020
|
Brokerages Set G1 Therapeutics Inc (NASDAQ:GTHX) Target Price at $59.29
- G1 Therapeutics Inc (NASDAQ:GTHX) has been given a consensus recommendation of “Buy” by the eleven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 12-month […]
- 08/23/2020
|
Sigma Labs to Host Virtual Roadshow Webinar on Wednesday, August 26, 2020 at 1:00 p.m. Eastern Time | | IT Business Net
- SANTA FE, NM / ACCESSWIRE / August 21, 2020 / Sigma Labs, Inc. ("Sigma Labs" or the "Company") (NASDAQ:SGLB), a leading developer of quality assurance software for the additive man
- 08/21/2020
|
Sigma Pensions, NANPF signss MOU to provide pension scheme for Professional Footballers - Businessday NG
- Sigma Pensions and the National Association of Nigeria Professional Footballers ( NANPF) have signed a Memorandum of Understanding...
- 08/21/2020
|
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s Disease
- NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Shake It Up Foundation for Parkinson’s Research and its international partners has committed to invest into Anavex up to 50% of the costs of a disease modifying clinical study to develop ANAVEX®2-73 (blarcamesine) for the disease modifying treatment of Parkinson’s disease. “Shake It Up is proud and excited to support research like this that may create opportunities for breakthroughs that could be a game-changer for people with Parkinson’s,” said Clyde Campbell, Founder and CEO of the Shake It Up Foundation. “The potential of a disease modifying treatment for Parkinson’s disease could be a very promising next step in further human testing of ANAVEX®2-73 (blarcamesine), in which the therapy goes through a rigorous process to determine whether it is safe, tolerable and efficacious.”“We see this collaboration as an important step in our global effort to expedite the development of ANAVEX®2-73 (blarcamesine) and to evaluate ANAVEX®2-73 (blarcamesine) for Parkinson’s disease as a potential disease modifying agent. Shake It Up Foundation shares our commitment to move rapidly to address the unmet need for treatments for Parkinson’s disease, and brings deep experience and an extensive network within the Parkinson’s community,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.The planned clinical study will use a convenient, once-daily oral ANAVEX®2-73 (blarcamesine) formulation to confirm the previously established potential disease modifying features of ANAVEX®2-73 (blarcamesine) in an animal model of Parkinson’s disease. Safety and efficacy will be investigated in an appropriately powered placebo-controlled clinical study of Parkinson’s disease patients over at least 48-weeks including ANAVEX®2-73-specific precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX®2-73 (blarcamesine) under a voluntary open label extension protocol.About Shake It Up Australia Foundation for Parkinson’s ResearchShake It Up Australia Foundation for Parkinson’s Research is a not-for-profit organization established in 2011 and in partnership with The Michael J. Fox Foundation (MJFF) promotes and funds Parkinson’s disease research in Australia aimed at better treatments and ultimately a cure. Further information is available at https://shakeitup.org.au/.About Parkinson’s DiseaseParkinson’s disease is a chronic and progressive neurological disorder that is characterized by well-known motor symptoms including tremors, stiffness of limbs, slowness of movements, and difficulties with posture and balance, as well as by non-motor symptoms. It is the second most common neurological disorder and approximately one million people in the United States, and from four to six million people worldwide, live with this disease. Parkinson’s disease is more common in people over 60 years of age and its prevalence is expected to increase significantly as the average age of the population increases. Current Parkinson’s treatments are only effective in managing symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms.About ANAVEX®2-73 (blarcamesine)ANAVEX®2-73 (blarcamesine) activates the Sigma-1 receptor (S1R) protein, which serves as a molecular chaperone and functional modulator involved in restoring homeostasis. In a Phase 2a Alzheimer’s disease (AD) study, ANAVEX®2-73 (blarcamesine) has shown dose dependent improvement in exploratory endpoints of cognition (MMSE) and activities of daily living (ADCS-ADL). Full genomic analysis of ANAVEX®2-73 (blarcamesine) Phase 2a AD patients was performed. The ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s disease dementia (PDD) study design includes genomic biomarkers identified in the ANAVEX®2-73 (blarcamesine) Phase 2a AD study. Studies of ANAVEX®2-73 (blarcamesine) in a disease modifying model of Parkinson’s disease indicates that ANAVEX®2-73 (blarcamesine) is well tolerated, induces significant motor recovery (p<0.05), induces neurohistological restoration (p<0.05) and reduces microglial activation (p<0.05), a potential biomarker of Parkinson’s disease. Behavioral patterns were completely normal, meaning no signs of either dystonia or stereotypic behaviors were detected in animals receiving the treatment. These studies were funded by The Michael J. Fox Foundation for Parkinson’s Research.About Anavex Life Sciences Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.For Further Information:Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:Email: ir@anavex.com
- 08/19/2020
|
Sigma share price jumps on $172 million deal
- The Sigma Healthcare Ltd (ASX: SIG) share price is outperforming today after it found a way to unlock $172 million in cash.
- 08/10/2020
|
TCorp partners up with LOGOS for Sigma deal
- Logistics real estate investor LOGOS Property has acquired two distribution centres off Sigma Healthcare for about $170 million.
- 08/09/2020
|
Sigma Announces the 85mm F1.4 DG DN | Art Lens, the Definitive Portrait Prime for the Mirrorless Age
- Fast-aperture full-frame prime lens that is surprisingly compact
Dust and Splash-proof construction
Completely new optical formula with 5 SLD and 1 Aspherical
- 08/06/2020
|
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates
- Conference Call and Webcast Today at 11:00 a.m. ETNEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal 2020 third quarter.“It is an accomplishment having three ongoing clinical studies in Rett syndrome in progress with ANAVEX®2-73 (blarcamesine) and we expect respective clinical trial results to be reported as we progress,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “It is important to point out that all clinical studies with ANAVEX®2-73 (blarcamesine), including the ongoing Alzheimer’s disease Phase 2b/3 trial and Parkinson’s disease dementia Phase 2 study, which read out is upcoming, includes the entire genome and exome sequencing, opens the possibility of using big data-driven unbiased genome-wide patient analysis, hence, maintaining the focus on Precision Medicine for neurological disorders.”Program Updates: * Yesterday Anavex announced it has received compassionate use Special Access Scheme (SAS) approval for Alzheimer’s disease patients continued treatment with ANAVEX®2-73 (blarcamesine) by the Australian Government Department of Health - Therapeutic Goods Administration (TGA). * In June 2020, Anavex announced it has received Clinical Trial Authorization (CTA) from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) as well as a ‘No Objection Letter’ from Health Canada to expand the footprint of the international Phase 2b/3 double-blind, randomized, placebo-controlled safety and efficacy trial (Study ANAVEX®2-73-AD-004) of ANAVEX2-73 (blarcamesine) for the treatment of early Alzheimer’s disease into the UK and Canada, respectively. * In June 2020, Anavex announced it exceeded by 50% its enrollment target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study in Rett syndrome. The Company expects to announce topline results from this study in calendar Q4 2020. * In July 2020, Anavex announced that the first pediatric patient was dosed in the Phase 2/3 ANAVEX®2-73-RS-003 EXCELLENCE clinical trial for the treatment of Rett syndrome with ANAVEX®2-73 (blarcamesine). * In July 2020, Anavex announced the enrollment of the first participant in a Phase 1 clinical trial of ANAVEX®3-71 (AF710B), an orally-administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases, with topline data anticipated in the first half of 2021.Financial Highlights: * Cash and cash equivalents of $27.6 million at June 30, 2020, compared to $22.2 million at fiscal year ended September 30, 2019. * Research and development expenses of $6.7 million for the quarter, compared to $5.8 million in the comparable quarter in 2019. * General and administrative expenses of $1.4 million for the quarter as well as for the comparable quarter in 2019. * Net loss of $6.5 million, or $0.11 per share for the quarter, compared to net loss of $6.5 million, or $0.13 per share in the comparable quarter of 2019.The financial information for the fiscal quarter ended June 30, 2020 should be read in conjunction with the Company’s interim condensed consolidated financial statements, which will appear on EDGAR, www.sec.gov and will be available on the Anavex website at www.anavex.com.Conference Call / Webcast InformationAnavex will host a conference call and webcast today at 11:00 a.m. ET.The live webcast of the conference call can be accessed online at https://wsw.com/webcast/cc/avxl14.To join the conference call, live via telephone, interested parties within the U.S. should dial, toll-free, 1 (866) 901-2585 and international callers should dial 1 (404) 835-7099. Please use confirmation number 49865428, followed by the pound sign ().A replay of the conference call will also be available on www.anavex.com.About Anavex Life Sciences Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.ANAVEX LIFE SCIENCES CORP. INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS As at June 30, 2020 and September 30, 2019 Expressed in US Dollars June 30, 2020September 30, 2019 (Unaudited) ASSETS Current Cash and cash equivalents$27,619,145$22,185,630 Incentive and taxe receivables3,547,9722,642,745 Prepaid expenses and deposits438,631500,998 Deferred costs24,508- Total assets$31,630,256$25,329,373 LIABILITIES AND STOCKHOLDERS' EQUITY Current Accounts payable$3,980,204$3,523,332 Accrued liabilities2,968,9941,516,342 Total liabilities6,949,1985,039,674 Common stock60,08352,652 Additional paid-in capital178,332,979153,633,807 Accumulated deficit(153,712,004)(133,396,760) Total stockholders' equity24,681,05820,289,699 Total liabilities and stockholders' equity$31,630,256$25,329,373 ANAVEX LIFE SCIENCES CORP. INTERIM CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS THREE MONTHS ENDED JUNE 30, 2020 and 2019 (Unaudited) Expressed in US Dollars 2020 2019 Operating Expenses General and administrative$1,381,477 $1,388,729 Research and development6,725,002 5,758,446 Total operating expenses8,106,479 7,147,175 Operating Loss(8,106,479)(7,147,175) Other income Grant income- 74,944 Research and development incentive income1,319,913 552,335 Interest income, net56,096 34,838 Gain on settlement of accounts payable- 36,978 Foreign exchange gain (loss), net248,665 (54,546) Total other income 1,624,674 644,549 Net loss before income taxes(6,481,805)(6,502,626) Income tax expense, current(4,817)(19,300) Net loss$(6,486,622)$(6,521,926) Net loss per Share Basic and Diluted$(0.11)$(0.13) Weighted Average Number of Shares Outstanding Basic and Diluted59,105,399 49,622,465 ANAVEX LIFE SCIENCES CORP. INTERIM CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS NINE MONTHS ENDED JUNE 30, 2020 AND 2019 (Unaudited) Expressed in US Dollars 2020 2019 Operating Expenses General and administrative$4,453,654 $5,211,287 Research and development19,126,717 17,549,442 Total operating expenses23,580,371 22,760,729 Other income Grant income149,888 223,999 Research and development incentive income2,980,456 1,727,007 Interest income, net172,996 165,103 Gain on settlement of accounts payable- 36,978 Foreign exchange gain (loss), net (24,182) (4,854) Total other income 3,279,158 2,148,233 Net loss before income taxes (20,301,213) (20,612,496) Income tax expense, current (14,031) (76,065) Net loss$(20,315,244)$(20,688,561) Net loss per Share Basic and Diluted$(0.35)$(0.43) Weighted Average Number of Shares Outstanding Basic and Diluted57,401,387 47,691,921 For Further Information:Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.comInvestors & Media: Email: ir@anavex.com
- 08/06/2020
|
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients
- Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical StudyNEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that patients from the ANAVEX®2-73-003 phase 2a Alzheimer’s disease trial will continue treatment with ANAVEX®2-73 (blarcamesine) via the Australian Government Department of Health - Therapeutic Goods Administration (TGA) compassionate use Special Access Scheme following completion of over 5-years daily dosing of ANAVEX®2-73 (blarcamesine) and recommendation by their physicians. The TGA approved the Special Access Scheme Category B applications based on the safety profile of ANAVEX®2-73 (blarcamesine), as well as clinical evidence that ANAVEX®2-73 (blarcamesine) may benefit patients. Anavex will facilitate continued access to ANAVEX®2-73 (blarcamesine) through the Special Access Scheme at the physicians’ request.“We are honored to support medical professionals and their patients seeking treatment for Alzheimer’s disease and who have very few medical options,” commented Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “The Phase 2a clinical ANAVEX®2-73-002/-003 studies are exploring the long-term effect of daily treatment with ANAVEX®2-73 (blarcamesine) over 5 years, however it is pleasing that physicians have requested extended treatment of their patients with ANAVEX®2-73 (blarcamesine) beyond these 5 years.”The Special Access Scheme:Most therapeutic goods are required to undergo an evaluation for quality, safety, and efficacy, and be included on the Australian Register of Therapeutic Goods (ARTG) before they can be supplied in Australia. In recognition that there are circumstances where patients need access to therapeutic goods that are not listed on the ARTG, the TGA facilitates a Special Access Scheme (SAS) for physicians seeking to use medicines that have not yet been approved in Australia. The SAS refers to arrangements, which provide for the supply of an unapproved therapeutic good for individual patients. Applications under the SAS are made to the TGA by their treating doctor, and approval to treat the patient takes into account the safety of the drug as well as supporting evidence that the drug may benefit the patients, along with the failure of any current therapies.11 https://www.tga.gov.au/form/special-access-schemeAbout ANAVEX®2-73 (blarcamesine)ANAVEX®2-73 (blarcamesine) activates the Sigma-1 receptor (S1R) protein, which serves as a molecular chaperone and functional modulator involved in restoring homeostasis. S1R activation has demonstrated ability to reduce key pathophysiological signs of Alzheimer’s disease: beta amyloid, hyperphosphorylated tau, and increased inflammation. In the Phase 2a 57-week Alzheimer’s disease (AD) ANAVEX®2-73-002 (ClinicalTrials.gov NCT02244541) study, ANAVEX®2-73 (blarcamesine) has shown dose dependent improvement in exploratory endpoints of cognition (MMSE) and function (ADCS-ADL). Its open-label extension study ANAVEX®2-73-003 (ClinicalTrials.gov NCT02756858) for an additional 208 weeks included full genomic analysis of patients with Alzheimer’s disease treated with ANAVEX®2-73 (blarcamesine). A 48-week Phase 2b/3 study ANAVEX®2-73-AD-004 (ClinicalTrials.gov NCT03790709) of ANAVEX®2-73 (blarcamesine) in 450 patients with early Alzheimer’s disease is ongoing and currently over 60% enrolled.About Anavex Life Sciences Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.For Further Information:Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.comInvestors & Media:Email: ir@anavex.com
- 08/05/2020
|
NASDAQ Rises for Fifth Straight Day and Logs Another New High
- Stocks Analysis by Zacks Investment Research covering: McDonald’s Corporation, Neurocrine Biosciences Inc, Diebold Nixdorf Inc, Treehouse Foods Inc. Read Zacks Investment Research's latest article on Investing.com
- 08/05/2020
|
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020
- Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern TimeNEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended June 30, 2020 on Thursday, August 6th, 2020. Management will host a conference call on Thursday, August 6th, 2020 at 11:00 am Eastern Time to review financial results and provide an update on its clinical programs and corporate highlights. Following management’s formal remarks, there will be a question and answer session with equity analysts.Conference Call / Webcast Information:The live webcast of the conference call can be accessed online at https://wsw.com/webcast/cc/avxl14.To join the conference call, live via telephone, interested parties within the U.S. should dial, toll-free, 1 (866) 901-2585 and international callers should dial 1 (404) 835-7099. Please use confirmation number 49865428, followed by the pound sign ().A replay of the conference call will also be available on www.anavex.com.About Anavex Life Sciences Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.For Further Information:Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.comInvestors & Media: Email: ir@anavex.com
- 08/04/2020
|
AKKA: First-half 2020 Revenue
- Regulatory News: AKKA (Paris:AKA) (BSE:AKA) (ISIN:FR0004180537): H1 2020 performance Low point in activity reached in May Solid performance of Data Re
- 07/27/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
- QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
- 07/22/2020
|
Kronos Bio Appoints Barbara Kosacz, Chief Operating Officer and General Counsel
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to trans
- 07/20/2020
|
Emerging Market and Legal Trends in the Top Five Global Startup Ecosystems
- The recently published Global Startup Ecosystem Report 2020 ranks the top global startup ecosystems by metrics including performance, funding, connectedness, talent, and knowledge to highlight the winning startup cities worldwide.
- 07/17/2020
|
Anavex Life Sciences (NASDAQ:AVXL) Downgraded by Zacks Investment Research to “Hold”
- Zacks Investment Research downgraded shares of Anavex Life Sciences (NASDAQ:AVXL) from a buy rating to a hold rating in a research note released on Monday, Zacks.com reports. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and […]
- 07/14/2020
|
Model N Announces Date of Third Quarter Fiscal Year 2020 Financial Results
- Model N, Inc. (NYSE: MODN), the leading provider of cloud revenue management solutions for Life Sciences and High Tech companies, plans to announce fi
- 07/14/2020
|
Qiagen N : provides update on Q2 2020 results, announces strong outlook for Q3 and FY 2020, and 2021 perspectives in light of coronavirus pandemic | MarketScreener
|
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020
- IGC announces its financial results for the Fiscal Year Ended March 31, 2020.
- 07/13/2020
|
H.C. Wainwright Reiterates a Buy Rating on Anavex Life Sciences (AVXL) - Markets
- In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL –
- 07/07/2020
|
New APM Study Reveals the Contribution of Projects and Project Management in the Health, Pharmaceutical and Life Sciences Sector
- Association for Project Management (APM), results of a study of the contribution of project management in the UK healthcare sector
- 07/07/2020
|
Salesforce.com: Moving Toward Good Health (NYSE:CRM)
- Salesforce.com has a significant presence in the healthcare segment and there are indications of continued strong momentum.
- 07/06/2020
|
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
- NEW YORK, July 06, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
- 07/06/2020
|
Median Technologies Is Awarded the Euronext European Rising Tech Label
- Regulatory News: Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext Europ
- 07/06/2020
|
Core Scientific and Horizon Kinetics expand investment in next-gen crypto mining equipment » CryptoNinjas
- Core Scientific, a US-based blockchain hosting provider, announced today it has partnered with New York-based investment manager Horizon Kinetics to
- 07/02/2020
|
Digital Microscopes Market to Surpass US$ 1,743.9 Million Globally by End Of 2027, Says CMI | | IT Business Net
- SEATTLE--(BUSINESS WIRE)--#DigitalMicroscopes--According to Coherent Market Insights, the global digital microscopes market is estimated to be valued at US$ 1,124.0 million in 2020, and is expected to
- 07/02/2020
|
MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform | | IT Business Net
- PARIS, FRANCE / ACCESSWIRE / July 2, 2020 / MastOR, a medical device company developing a surgical robot for laparoscopy assistance, announced today a €3M equity round through a seed investment from t
- 07/02/2020
|
Sofinnova Partners : MastOR Secures Seed Funding from Sofinnova Partners to Develop its Laparoscopy Assistance Platform
|
Boom biotecnológico a la vista: Caixa Capital Risc, Inveready e Ysios anticipan un mayor apetito inversor y nuevas oportunidades
- La pandemia traerá un boom de inversión en biotecnología: los principales fondos españoles dan las claves para invertir en un sector muy especializado.
- 07/02/2020
|
Sofinnova Partners : Announces Two First Investments from its MD Start III Medtech Acceleration Fund
|
Sofinnova Partners Announces Two First Investments from its MD Start III Medtech Acceleration Fund
- Sofinnova Partners announces two first investments from its MD Start III Medtech Acceleration Fund
- 07/02/2020
|
HC2 Holdings Provides Update on Strategic Initiatives | MarketScreener
|
Agilent Technologies Inc (NYSE:A) Holdings Cut by Guggenheim Capital LLC
- Guggenheim Capital LLC cut its position in Agilent Technologies Inc (NYSE:A) by 31.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,478 shares of the medical research company’s stock after selling 23,802 shares during the quarter. Guggenheim Capital LLC’s holdings in Agilent Technologies […]
- 07/01/2020
|
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome
- NEW YORK, July 01, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
- 07/01/2020
|
Agilent Technologies (NYSE:A) Stock Rating Reaffirmed by Goldman Sachs Group
- Agilent Technologies (NYSE:A)‘s stock had its “neutral” rating reaffirmed by equities researchers at Goldman Sachs Group in a research report issued on Wednesday, Stock Target Advisor reports. Other equities research analysts have also recently issued research reports about the company. Cfra cut their target price on Agilent Technologies from $89.00 to $85.00 and set a […]
- 07/01/2020
|
Recent Analysts’ Ratings Changes for Chart Industries (GTLS)
- A number of research firms have changed their ratings and price targets for Chart Industries (NASDAQ: GTLS): 6/29/2020 – Chart Industries was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $62.00 price target on the stock. 6/24/2020 – Chart Industries was upgraded by analysts at […]
- 07/01/2020
|
Frasers Centrepoint Trust to raise stake in owner of 5 suburban malls in Singapore for $197.2m
- SINGAPORE (THE BUSINESS TIMES) - Frasers Centrepoint Trust (FCT) is acquiring an additional 12.07 per cent stake in PGIM Real Estate Asia Retail Fund (ARF) for $197.2 million, in line with plans to bolster its presence in Singapore's suburban retail sector.. Read more at straitstimes.com.
- 07/01/2020
|
Frasers Centrepoint Trust to raise stake in PGIM Real Estate Fund for S$197.2m
- FRASERS Centrepoint Trust (FCT) is acquiring an additional 12.07 per cent stake in PGIM Real Estate Asia Retail Fund (ARF) for S$197.2 million, in line with plans to bolster its presence in Singapore's suburban retail sector. Read more at The Business Times.
- 06/30/2020
|
Accenture (ACN) Receives a Hold from Wells Fargo - Markets
- Wells Fargo analyst Edward Caso maintained a Hold rating on Accenture (ACN – Research Report) on June 25. The company’s
- 06/30/2020
|
ÖAW nahm 96 neue Stipendiat/innen auf
- Stipendien in Höhe von insgesamt mehr als 10 Mio. Euro wurden an herausragende Nachwuchswissenschaftler/innen vergeben.
- 06/30/2020
|
All About the Berkeley Lights Stock IPO
- For some reason, IPOs are coming out of the woodwork these days. Seems strange when you consider that just three months ago, all hell was breaking loose, and everyone seems to have forgotten about that. In fact, since the first-ever mention of the Woohoo Flu, the Nasdaq has gone up by +13%. Maybe everyone's rushing to IPO before the door slams shut again? It was only several months ago that we wrote about 'How Berkeley Lights Enables Synthetic Biology,' and now they've filed for an IPO, which means we get to take a look under the hood. We'll assume you're
- 06/30/2020
|
Sigma Computing Expands Snowflake Partnership to Help Customers Leverage Speed, Scale, and Modern Data Governance Possible Only in the Cloud
- Sigma Computing, an innovator in cloud-native analytics and business intelligence (A&BI), today announced two initiatives that deepen its partners
- 06/30/2020
|
Sigma Computing Names Orla Clifford Vice President of Operations | | IT Business Net
- Clifford to Optimize Operations, Drive Scalability, and Support Rapid Growth SAN FRANCISCO--(BUSINESS WIRE)--Sigma Computing, an innovator in cloud-native analytics and business intelligence (A&BI
- 06/29/2020
|
insideBIGDATA Latest News – 6/29/2020 - insideBIGDATA
- In this regular column, we’ll bring you all the latest industry news centered around our main topics of focus: big data, data science, machine learning, AI, and deep learning. Our industry is constantly accelerating with new products and services being announced everyday. Fortunately, we’re in close touch with vendors from this vast ecosystem, so we’re in a unique position to inform you about all that’s new and exciting. Our massive industry database is growing all the time so stay tuned for the latest news items describing technology that may make you and your organization more competitive.
- 06/29/2020
|
Seoul’s startup and tech ecosystem is world class — here’s what you need to know
- The city is already home to 8,708 startups, 85 accelerators, and the country has a total of 10 unicorns. And now, Seoul entered the top 20 startup ecosystems in the world.
- 06/29/2020
|
Leading brokers name 3 ASX shares to buy right now
- Leading brokers have named Treasury Wine Estates Ltd (ASX:TWE) and these ASX shares as the ones to buy right now. Here's why...
- 06/29/2020
|
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
- Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentations
- 06/29/2020
|
Agilent Technologies Inc (NYSE:A) Shares Sold by Skandinaviska Enskilda Banken AB publ
- Skandinaviska Enskilda Banken AB publ reduced its position in Agilent Technologies Inc (NYSE:A) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,672 shares of the medical research company’s stock after selling 1,096 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s […]
- 06/28/2020
|
Agilent Technologies Inc (NYSE:A) Declares $0.18 Quarterly Dividend
- Agilent Technologies Inc (NYSE:A) declared a quarterly dividend on Wednesday, May 20th, Zacks reports. Investors of record on Tuesday, June 30th will be paid a dividend of 0.18 per share by the medical research company on Wednesday, July 22nd. This represents a $0.72 dividend on an annualized basis and a yield of 0.84%. The ex-dividend […]
- 06/28/2020
|
Liverpool hit harder than most by coronavirus but city has hope
- SPECIAL REPORT: We take an in-depth look at how the city plans to recover from the crisis and transform its position in the country
- 06/28/2020
|
Movers And Shakers Of The Week [June 22-27]
- We bring to you the latest edition of movers and shakers of the week in the Indian startup ecosystem.
- 06/27/2020
|
Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to Buy
- Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 06/26/2020
|
"A classe de fundos quantitativos no Brasil vai acabar", diz gestor da Giant Steps
- Rodrigo Terni, sócio fundador da Giant Steps Capital, trouxe três pontos que precisavam ser explorados para desmistificar a palavra quant
- 06/26/2020
|
Accenture : Third Quarter Fiscal 2020 Transcript | MarketScreener
|
Gut health and exercise: studies suggest exercise could change microbiome
- Mounting evidence suggests that exercise can modify the types of bacteria that reside within our guts
- 06/26/2020
|
Global Respiratory Syncytial Virus Diagnostics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Becton, Dickinson and Co. | Technavio
- The Global Respiratory Syncytial Virus (RSV) Diagnostics Market will grow by $ 585.17 million during 2020-2024
- 06/26/2020
|
Comunicado do Business Wire :ExaGrid
|
Schneider Electric : Streamline Load Tests with a Wireless Load Bank Solution | MarketScreener
|
The SIGMA Group Chooses ExaGrid to Back Up Customer Data
- INFIDIS introduces The SIGMA Group to ExaGrid as an Optimized Backup SolutionMARLBOROUGH, Mass. — ExaGrid® today announced that INFIDIS, a global IT integrator and solutions provider, led The…
- 06/25/2020
|
Hutchison China MediTech : Chi-Med Announces US$100 Million Equity Investment by General Atlantic | MarketScreener
|
Chemist Warehouse sales fall but profits up amid pandemic
- Financial 2019 sales were lower while profits inched higher at the discount chain owned by the notoriously private Verrocchi and Gance families.
- 06/25/2020
|
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...
- 06/25/2020
|
The Challenges And Opportunities For Life Sciences Industry - ValueWalk
- The life sciences industry, comprised largely of small and middle market companies, is the focus of a new report from the NCMM.
- 06/24/2020
|
Cantel Medical Corp. (NYSE: CMD) Q3 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Cantel Medical Corp. - CMD stock
- 06/24/2020
|
Wave Life Sciences Ltd (NASDAQ:WVE) Sees Large Drop in Short Interest
- Wave Life Sciences Ltd (NASDAQ:WVE) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 4,690,000 shares, a drop of 5.8% from the May 31st total of 4,980,000 shares. Based on an average trading volume of 571,400 shares, the days-to-cover ratio […]
- 06/24/2020
|
Why Buy These 2 TSX Stocks for Your TFSA Portfolio Now?
- TFSA investors should consider buying these two TSX stocks now for capital appreciation and steady income.
- 06/23/2020
|
Cognizant collaborates with Alphabet-owned Verily to facilitate Covid-19 testing across US
- The program is in operation at over 140 testing sites across 13 states and has supported the US administration with 284,000 COVID-19 tests.
- 06/23/2020
|
Hyundai Motor, Kia Motors and LG Chem Launch Global Competition to Invest in EV and Battery Start-ups | MarketScreener
|
Breathtaking snaps of our galaxy revealed in Milky Way Photographer competition
- STUNNING snaps of the Milky Way’s deep centre have been revealed as part of a photography competition. As we live in the Orion Arm of the galaxy, with the right conditions we can look into it…
- 06/23/2020
|
Preis für einen, der Blinde sehend macht - Blick
- Botond Roska, Direktor am Institut für Molekulare und Klinische Ophthalmologie Basel (IOB) und Professor an der medizinischen und der naturwissenschaftlichen Fakultät der Uni Basel, erhält den mit einer Million dotierten Körber-Preis für die Europäische Wissenschaft.
- 06/23/2020
|
Steris PLC (NYSE:STE) Short Interest Update
- Steris PLC (NYSE:STE) was the target of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,360,000 shares, an increase of 7.1% from the May 31st total of 1,270,000 shares. Based on an average trading volume of 736,000 shares, the short-interest ratio is presently […]
- 06/23/2020
|
RWS Holdings plc (RWS) to Issue Dividend of GBX 1.75 on July 17th
- RWS Holdings plc (LON:RWS) announced a dividend on Tuesday, June 9th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, June 25th will be paid a dividend of GBX 1.75 ($0.02) per share on Friday, July 17th. This represents a yield of 0.29%. The ex-dividend date is Thursday, June 25th. The official announcement can be seen at […]
- 06/23/2020
|
Danaher Co. (NYSE:DHR) Plans Quarterly Dividend of $0.18
- Danaher Co. (NYSE:DHR) announced a quarterly dividend on Tuesday, May 5th, RTT News reports. Stockholders of record on Friday, June 26th will be given a dividend of 0.18 per share by the conglomerate on Friday, July 31st. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date […]
- 06/23/2020
|
Grant Thornton names Lisa Walkush to lead firmwide Industry program
- Grant Thornton LLP has named Lisa Walkush as its national managing principal of its Industry program, effective immediately. She will also serve on th
- 06/23/2020
|
LEG, H.I.G. Purchase 1.2M-SF Pharma Campus Outside Princeton
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 06/22/2020
|
Research reveals search engine habits of patients and HCPs -
- New research by Life Sciences by Stickyeyes, conducted for pharmaphorum, sheds light on people’s behaviour when searching for oncology information online.
- 06/22/2020
|
Das Kriegsende brachte den tiefsten Einschnitt der Firmengeschichte
(FOTO)
- SCHOTT erinnert an den legendären "Zug der 41 Glasmacher" vor 75 Jahren
- 06/22/2020
|
9,020 Shares in Steris PLC (NYSE:STE) Acquired by CIBC World Markets Inc.
- CIBC World Markets Inc. purchased a new position in shares of Steris PLC (NYSE:STE) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 9,020 shares of the medical equipment provider’s stock, valued at approximately $1,263,000. A number of other hedge funds and other institutional investors have […]
- 06/22/2020
|
Anavex Life Sciences Corp (NASDAQ:AVXL) Shares Purchased by Bank of New York Mellon Corp
- Bank of New York Mellon Corp boosted its position in shares of Anavex Life Sciences Corp (NASDAQ:AVXL) by 12.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 160,062 shares of the biotechnology company’s stock after purchasing an additional 17,951 shares during the period. […]
- 06/22/2020
|
Global Silicon Photonics Market (2019 to 2025) - Growing Deployment of 5G Networks Presents Opportunities - ResearchAndMarkets.com
|
Will the launch of Favipiravir mark the turnaround for Glenmark Pharma?
- If the drug proves to be efficacious for Covid treatment, Glenmark will cash in on first mover advantage.
- 06/21/2020
|
Students-run think-tank launches helpline to find jobs for lockdown-hit workers in Delhi-NCR
- The helpline will be operational from 10 am to 7 pm everyday. Student volunteers will attend calls from potential employers and workers and take note of their requirements.
- 06/21/2020
|
Students-run think-tank launches helpline to find jobs for lockdown-hit workers in Delhi-NCR
- The helpline -- 8800883323 -- 'ekatra' was conceptualized by the students to help the hiring of the unskilled, semi-skilled and skilled workers across Delhi-NCR.
- 06/21/2020
|
Students-run think-tank launches helpline to find jobs for lockdown-hit workers in Delhi-NCR
- The pilot project and the helpline number is an attempt by the student-led think-tank to help locals and migrant workers find employment, Nagpal, who is also part of the PMO's COVID-19 Response Task Force, said during the online launch.
- 06/21/2020
|
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 7.5%
- Shares of Anavex Life Sciences Corp (NASDAQ:AVXL) traded down 7.5% during mid-day trading on Friday . The stock traded as low as $4.78 and last traded at $4.80, 1,804,257 shares traded hands during trading. An increase of 78% from the average session volume of 1,016,313 shares. The stock had previously closed at $5.19. Several analysts […]
- 06/21/2020
|
Aftermarket infotainment touchscreen demand is ‘low but hasn’t disappeared’: Pioneer India
- Of late, Pioneer India has also been facing challenges from Chinese imports, which can be bought at half the price. Apart from security issues, the user experience can also get compromised in such products.
- 06/20/2020
|
Zacks: Brokerages Expect Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.63 Per Share
- Brokerages predict that Agilent Technologies Inc (NYSE:A) will report $0.65 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $0.49 to $0.73. Agilent Technologies reported earnings of $0.76 per share during the same quarter last year, which would suggest a […]
- 06/20/2020
|
COVID-19 Impacts Demand on Ultraviolet (UV) Disinfection Equipment Market 2020-2024 | Evolving Opportunities With Advanced UV Inc. and American Ultraviolet Inc. | Technavio
|
COVID-19 Impacts Demand on Ultraviolet (UV) Disinfection Equipment Market 2020-2024 | Evolving Opportunities With Advanced UV Inc. and American Ultraviolet Inc. | Technavio
- The Global Ultraviolet (UV) Disinfection Equipment Market will grow by USD 2.06 bn during 2020-2024
- 06/20/2020
|
Croda International (LON:CRDA) Stock Price Passes Above 200-Day Moving Average of $4,852.05
- Croda International Plc (LON:CRDA) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4,852.05 and traded as high as $5,184.00. Croda International shares last traded at $5,158.00, with a volume of 229,431 shares traded. CRDA has been the topic of several recent research reports. JPMorgan […]
- 06/19/2020
|
Wave Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by BidaskClub
- Wave Life Sciences (NASDAQ:WVE) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports. WVE has been the topic of several other reports. Mizuho reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Wave Life Sciences in a research note […]
- 06/19/2020
|
NASDAQ Higher for Fifth Straight Day as Stocks Rally in Final Hour
- Stocks Analysis by Zacks Investment Research covering: Exxon Mobil Corp, Natural Gas Futures, Cirrus Logic Inc, DSP Group Inc. Read Zacks Investment Research's latest article on Investing.com
- 06/19/2020
|
Apprentice.io Raises $7.5M in Funding | FinSMEs
- Apprentice.io, a Jersey City, NY-based provider of an intelligent software platform for Life Sciences manufacturing, raised $7.5m in funding
- 06/18/2020
|
Iowa Soybean Research Center has new partner
- Merschman Seeds joins advisory council of soybean research program based at Iowa State University.
- 06/18/2020
|
Plants use odour camouflage tricks to 'hide in plain sight'
- Plants have an upper hand in the ecological battle against insects by using odour camouflage tricks to 'hide in plain sight' and avoid being eaten, scientists say.
- 06/18/2020
|
Sigma 100-400mm DG DN OS is a Lighter Mirrorless Telephoto | Digital Trends
- Meet the Sigma 100-400mm DG DN OS, a telephoto lens made for mirrorless with a lighter profile and image stabilization. It's expected to start shipping in July.
- 06/18/2020
|
Cegedim : Health Data collabore avec IBM Watson Health pour fournir un accès aux données de vie réelle | Zone bourse
|
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
- Is (AVXL) Outperforming Other Medical Stocks This Year?
- 06/18/2020
|
Why should you seek an international assignment? - Business Review
- A bit of history: The British Empire was the largest and most complex form of human organization in history, ruling over approximately one quarter of the
- 06/18/2020
|
Calypso Biotech schließt Herstellung von CALY-002-Chargen für die
klinische Entwicklung ab
- AGC Biologics stellt auf IL-15 ausgerichteten humanisierten monoklonalen Antikörper her
- 06/18/2020
|
Oracle : Unveils Clinical One Data Collection Cloud Service | MarketScreener
|
Scientists as heroes: Let's keep that image in the public eye - STAT
- Their work on Covid-19 is bringing scientists the public acclaim they deserve. Prizes for scientific work can help keep them in the spotlight.
- 06/18/2020
|
Danaher (NYSE:DHR) Stock Rating Upgraded by Wolfe Research
- Danaher (NYSE:DHR) was upgraded by research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $195.00 price objective on the conglomerate’s stock. Wolfe Research’s price target suggests a potential upside of 10.59% from the company’s current […]
- 06/18/2020
|
RWS (LON:RWS) Shares Cross Above Two Hundred Day Moving Average of $576.16
- RWS Holdings plc (LON:RWS) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $576.16 and traded as high as $589.00. RWS shares last traded at $578.00, with a volume of 122,245 shares changing hands. A number of brokerages have weighed in […]
- 06/18/2020
|
Sigma Announces 100-400mm Lens for Sony E and L-Mount Mirrorless Cameras; Available at B&H Photo
- Sigma’s latest zoom for full-frame mirrorless cameras, the Sigma 100-400mm f/5-6.3 DG DN OS Contemporary lens available for Sony E and Leica Cameras.
- 06/18/2020
|
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
- Press Release Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. The Series A financing was led by Frazier Healthcare...
- 06/17/2020
|
Alliancebernstein L.P. Sells 3,265 Shares of Steris PLC (NYSE:STE)
- Alliancebernstein L.P. trimmed its stake in Steris PLC (NYSE:STE) by 2.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 136,177 shares of the medical equipment provider’s stock after selling 3,265 shares during the period. Alliancebernstein L.P. owned 0.16% of Steris […]
- 06/17/2020
|
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
- Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treat
- 06/17/2020
|
Führende Pharma-Verpackungsunternehmen verpflichten sich zu
Lieferungen für den Kampf gegen COVID-19
- Stevanato Group, SCHOTT und Gerresheimer bestätigen ihre Bereitschaft, den zukünftigen COVID-19-Impfstoff mit pharmazeutischen Glasbehältern zu unterstützen
- 06/16/2020
|
The Power of Dell Technologies On Demand for PowerScale | Direct2DellEMC
- Today we announced Dell EMC PowerScale. This new family of storage systems engineered with industry-leading storage software and server hardware is a new
- 06/16/2020
|
CognitOps Raises $3M in Seed Funding | FinSMEs
- CognitOps, an Austin, Texas-based AI startup whose software models automates warehouse management, completed its seed round of $3m
- 06/16/2020
|
